Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study

Bimekizumab is a novel interleukin (IL)-17A/IL-17F inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in adult patients. While its efficacy and safety have been demonstrated in several clinical trials, real-world data remains sparse. Herein, we provide evidence regarding the use of bimekizumab in the routine clinical setting.